By using U0126 to regulate the status of the signaling pathway, we proved that inhibiting the MAPK/ERK/NF-κB signaling pathway reduces the expression of MEK1/2, ERK1/2, and NF-κBp65, thereby inhibiting the proliferation and invasion of ectopic lesions so as to achieve the purpose of treating EMs. Here, MAP2K1 is linked to eosinophilia-myalgia syndrome.